HBHL: Healthy Bones, Healthy Life

Sponsor
University of Nebraska (Other)
Overall Status
Recruiting
CT.gov ID
NCT04472286
Collaborator
(none)
50
1
22.9
2.2

Study Details

Study Description

Brief Summary

Childhood cancer treatments are increasingly effective, leading to dramatic improvements in survival rates. These treatments often have devastating effects on the overall health of pediatric cancer survivors (PCS) since they occur during a critical time of bone growth, including increased risks of poor bone health, fracture, and diabetes. In normal child development, physical activity habits influence bone density and structure, which affect bone strength in adulthood. Despite this well-understood principle of bone development, there are no exercise guidelines for improving bone health in PCS. The long-term goal of this research is to develop an effective exercise intervention to improve bone health after cancer therapy. As a first step, the investigators propose to test the hypothesis that the intensity and amount of ground impact of a child's daily physical activity will influence changes in bone density in PCS. The Specific Aims are to (1) examine the effect of physical activity on lumbar bone density of PCS and to (2) evaluate how physical activity influences bone density. In a prospective cohort study, the investigators will enroll 38 pediatric and adolescent survivors (ages 5-18) of acute lymphoblastic leukemia or lymphoma at any post-treatment time point. Aim 1: At two assessments, baseline and six months later, bone density and structure (by DXA scan, a type of x-ray that can measure bone density and the amount of muscle and fat in the body) and physical activity level (by accelerometry, a device like a fitness tracker) will be evaluated. Each child will be categorized as having low or high physical activity based on accelerometry measures averaged from baseline and six-month assessments. Bone changes (0-6 months) will be compared between low and high activity groups. Aim 2: Evaluate potential mechanisms by which physical activity mediates changes in bone, including the effects of lean mass (measured by DXA) and metabolic health (lipid panel, insulin sensitivity (HOMA-IR, hemoglobin A1c), vitamin D). Long-term impact: This research will provide information as to the types of exercise that impact bone health in PCS. This study will help develop effective, evidence-based exercise therapies. These therapies may help prevent fractures and associated disability, leading to an improvement in the quality of life for survivors of pediatric cancer.

Detailed Description

This project will examine habitual physical activity, bone health, and insulin resistance in pediatric acute lymphocytic leukemia (ALL) and lymphoma cancer survivors at two time points: baseline and 6 months. At the two study timepoints, all study participants will be asked to wear an accelerometer, receive a DXA scan of the lumbar spine and hip, and have blood drawn for analysis. Study participants will be given a gift card stipend for each study visit attended. Study visits will coincide with regular office visits to Children's Hospital Oncology Clinic and the Children's Hospital Survivorship Clinics whenever possible. The potential mechanism by which physical activity mediates bone changes will be explored by concurrently measuring changes in lean/fat mass and metabolic status. This pilot study will provide data to inform the design of a randomized controlled trial to test the effect of a physical activity intervention on bone health in PCS.

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Healthy Bones, Healthy Life: Effect of Habitual Physical Activity on Bone and Metabolic Health in Pediatric Cancer Survivors
Actual Study Start Date :
Nov 1, 2020
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Pediatric Cancer Survivors

Children and adolescents who have completed treatment of for acute lymphoblastic leukemia (ALL) and lymphoma.

Outcome Measures

Primary Outcome Measures

  1. Bone Mineral Density (g/cm2) [6 months]

    z-score of lumbar Spine bone density- DXA scan

  2. Hip structural analysis [6 months]

    DXA scan

  3. Physical Activity Level [6 months]

    Physical Activity as measured by accelerometry

Secondary Outcome Measures

  1. Lipid panel [6 months]

    cholesterol (total, HDL, and LDL) and triglycerides will be measured, which are an indicator of overall cardiovascular health which can impact insulin sensitivity

  2. Homeostatic Model Assessment for Insulin Resistance [6 months]

    Fasting Insulin and Fasting Glucose will be combined to calculate the HOMA-IR, which is an indicator of insulin sensitivity

  3. Hemoglobin A1c [6 months]

    measure of the glycated hemoglobin in blood, which is an indicator of insulin sensitivity

  4. Vitamin D [6 months]

    measures the levels of vitamin D in the blood which is an indicator of bone health

Eligibility Criteria

Criteria

Ages Eligible for Study:
5 Years to 18 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  1. Children between the ages of 5-18

  2. Diagnosis of ALL or Lymphoma

  3. Between 1-13 months post-cancer treatment

Exclusion Criteria:
  1. Children younger than 5 years old or 19 or older

  2. Children without a diagnosis of ALL or lymphoma

  3. Children receiving ongoing cancer treatment

  4. Children with Down syndrome (identified as a precancerous condition affecting BMD)

  5. Children with a prior history of bisphosphonate use or other medication directed at increasing bone density

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Nebraska Medical Center Omaha Nebraska United States 68198

Sponsors and Collaborators

  • University of Nebraska

Investigators

  • Principal Investigator: Laura Bilek, PhD, University of Nebraska

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Laura D. Bilek, PhD, PT, Associate Professor, University of Nebraska
ClinicalTrials.gov Identifier:
NCT04472286
Other Study ID Numbers:
  • 206-20-FB
First Posted:
Jul 15, 2020
Last Update Posted:
Dec 13, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 13, 2021